EZH2 (enhancer of zeste homologue 2), also known as Enx1, is a member of the polycomb group of proteins and is involved in cell cycle regulation. EZH2 represses transcription via trimethylation of histone H3 on Lys27 (H3K27) as indicated by the fact that RNAi-mediated knockdown of EZH2 resulted in a loss of H3K27 trimethylation. EZH2 is ubiquitously expressed during early embryo genesis, and becomes restricted to the central and peripheral nervous systems and sites of fetal hematopoiesis during later development. In the adult, EZH2 is restricted to the spleen, testis and placenta. EZH2 and BMI-1 genes are coexpressed in Reed-Sternberg cells of Hodgkin’s disease. Coexpression of BMI-1 and EZH2 is also associated with cycling cells and degree of malignancy in B-cell non-Hogkin’s lymphoma. EZH2 is involved in the progression of prostate cancer, and has been identified as a marker of aggressive breast cancer. Two transcript variants encoding distinct isoforms have been identified for this gene
Product Information
Format
Purified
Control
HeLa Nuclear Extracts
Presentation
Mouse monoclonal IgG1κ ascites in buffer containing 0.1 M Tris-Glycine (pH7.4) 150 mM NaCl with 0.05% sodium azide.
Applications
Application
Use Anti-EZH2 Antibody, clone BD43 (Mouse Monoclonal Antibody) validated in WB to detect EZH2 also known as Lysine N-methyltransferase 6, enhancer of zeste homolog 2, ENX-1.
Key Applications
Western Blotting
Biological Information
Immunogen
Recombinant fusion protein of amino acids 1-286 of human EZH2 tagged with MBP.
Clone
BD43
Concentration
Please refer to the Certificate of Analysis for the lot-specific concentration.
This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq
Function:Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Compared to EZH2-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. Catalytic activity:S-adenosyl-L-methionine + histone L-lysine = S-adenosyl-L-homocysteine + histone N(6)-methyl-L-lysine. Subunit structure:Binds ATRX via the SET domain Probable. Component of the PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4 and RBBP7 and possibly AEBP2. The minimum components required for methyltransferase activity of the PRC2/EED-EZH2 complex are EED, EZH2 and SUZ12. The PRC2 complex may also interact with DNMT1, DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via the SUZ12 subunit. Interacts with HDAC1 and HDAC2. Subcellular location:Nucleus. Tissue specificity:Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis. Developmental stage:Expression decreases during senescence of embryonic fibroblasts (HEFs). Expression peaks at the G1/S phase boundary. Induction:Expression is induced by E2F1, E2F2 and E2F3. Expression is reduced in cells subject to numerous types of stress including UV-, IR- and bleomycin-induced DNA damage and by activation of TP53/p53. Post-translational modification:Phosphorylated by AKT1. Phosphorylation by AKT1 reduces methyltransferase activity.
Sequence similarities Belongs to the histone-lysine methyltransferase family. EZ subfamily.
Contains 1 SET domain. Caution:Two variants of the PRC2 complex have been described, termed PRC3 and PRC4. Each of the three complexes may include a different complement of EED isoforms, although the precise sequences of the isoforms in each complex have not been determined. The PRC2 and PRC4 complexes may also methylate 'Lys-26' of histone H1 in addition to 'Lys-27' of histone H3 (Ref.15 and Ref.19), although other studies have demonstrated no methylation of 'Lys-26' of histone H1 by PRC2.
Product Usage Statements
Quality Assurance
Western Blot Analysis: 1:5,000 from a previous lot detected EZH2 of HeLa Nuclear extract.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at 2-8°C from date of receipt.
For maximum recovery of product, centrifuge the vial prior to removing the cap. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Packaging Information
Material Size
100 µg
原厂资料：
Key Spec Table
Species Reactivity
Key Applications
Host
Format
Antibody Type
H, M
WB
M
Purified
Monoclonal Antibody
Description
Catalogue Number
05-1319
Replaces
04-1047
Description
Anti-EZH2 Antibody, clone BD43
Alternate Names
Enhancer of zeste homolog 2
ENX-1
enhancer of zeste homolog 2
enhancer of zeste 2
Lysine N-methyltransferase 6
Background Information
EZH2 (enhancer of zeste homologue 2), also known as Enx1, is a member of the polycomb group of proteins and is involved in cell cycle regulation. EZH2 represses transcription via trimethylation of histone H3 on Lys27 (H3K27) as indicated by the fact that RNAi-mediated knockdown of EZH2 resulted in a loss of H3K27 trimethylation. EZH2 is ubiquitously expressed during early embryo genesis, and becomes restricted to the central and peripheral nervous systems and sites of fetal hematopoiesis during later development. In the adult, EZH2 is restricted to the spleen, testis and placenta. EZH2 and BMI-1 genes are coexpressed in Reed-Sternberg cells of Hodgkin’s disease. Coexpression of BMI-1 and EZH2 is also associated with cycling cells and degree of malignancy in B-cell non-Hogkin’s lymphoma. EZH2 is involved in the progression of prostate cancer, and has been identified as a marker of aggressive breast cancer. Two transcript variants encoding distinct isoforms have been identified for this gene
Product Information
Format
Purified
Control
HeLa Nuclear Extracts
Presentation
Mouse monoclonal IgG1κ ascites in buffer containing 0.1 M Tris-Glycine (pH7.4) 150 mM NaCl with 0.05% sodium azide.
Applications
Application
Use Anti-EZH2 Antibody, clone BD43 (Mouse Monoclonal Antibody) validated in WB to detect EZH2 also known as Lysine N-methyltransferase 6, enhancer of zeste homolog 2, ENX-1.
Key Applications
Western Blotting
Biological Information
Immunogen
Recombinant fusion protein of amino acids 1-286 of human EZH2 tagged with MBP.
Clone
BD43
Concentration
Please refer to the Certificate of Analysis for the lot-specific concentration.
This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq
Function:Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Compared to EZH2-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. Catalytic activity:S-adenosyl-L-methionine + histone L-lysine = S-adenosyl-L-homocysteine + histone N(6)-methyl-L-lysine. Subunit structure:Binds ATRX via the SET domain Probable. Component of the PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4 and RBBP7 and possibly AEBP2. The minimum components required for methyltransferase activity of the PRC2/EED-EZH2 complex are EED, EZH2 and SUZ12. The PRC2 complex may also interact with DNMT1, DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via the SUZ12 subunit. Interacts with HDAC1 and HDAC2. Subcellular location:Nucleus. Tissue specificity:Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis. Developmental stage:Expression decreases during senescence of embryonic fibroblasts (HEFs). Expression peaks at the G1/S phase boundary. Induction:Expression is induced by E2F1, E2F2 and E2F3. Expression is reduced in cells subject to numerous types of stress including UV-, IR- and bleomycin-induced DNA damage and by activation of TP53/p53. Post-translational modification:Phosphorylated by AKT1. Phosphorylation by AKT1 reduces methyltransferase activity.
Sequence similarities Belongs to the histone-lysine methyltransferase family. EZ subfamily.
Contains 1 SET domain. Caution:Two variants of the PRC2 complex have been described, termed PRC3 and PRC4. Each of the three complexes may include a different complement of EED isoforms, although the precise sequences of the isoforms in each complex have not been determined. The PRC2 and PRC4 complexes may also methylate 'Lys-26' of histone H1 in addition to 'Lys-27' of histone H3 (Ref.15 and Ref.19), although other studies have demonstrated no methylation of 'Lys-26' of histone H1 by PRC2.
Product Usage Statements
Quality Assurance
Western Blot Analysis: 1:5,000 from a previous lot detected EZH2 of HeLa Nuclear extract.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at 2-8°C from date of receipt.
For maximum recovery of product, centrifuge the vial prior to removing the cap. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
